Lercanidipine hydrochloride 200 mg | Purity Not Available
TargetMol
Lercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class.
More Information Supplier PageLercanidipine hydrochloride
Search Results
Ospemifene 10 mg | 99.73%
TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information Supplier PageOspemifene
Ospemifene 100 mg | 99.73%
TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information Supplier PageOspemifene
Nicaraven 10 mg | 99.77%
TargetMol
Nicaraven, a hydroxyl radical scavenger, has neuroprotective and antivasospastic effects.
More Information Supplier PageNicaraven
Nicaraven 100 mg | 99.77%
TargetMol
Nicaraven, a hydroxyl radical scavenger, has neuroprotective and antivasospastic effects.
More Information Supplier PageNicaraven
Lappaconitine hydrobromide 50 mg | Purity Not Available
TargetMol
Lappaconitine hydrobromide (Allapinine) is a kind of alkaloid extracted from Aconitum sinomontanum Nakai. It has anti-inflammatory effects.
More Information Supplier PageLappaconitine hydrobromide
Ospemifene 200 mg | 99.73%
TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information Supplier PageOspemifene
RBC8 100 mg | 99.81%
TargetMol
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
More Information Supplier PageRBC8
SB-705498 50 mg | 98.00%
TargetMol
SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
More Information Supplier PageSB-705498
SB-705498 25 mg | 98.00%
TargetMol
SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
More Information Supplier PageSB-705498